SCHEMBL2708260

SCHEMBL2708260

N#CCC[C@H](N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21411550 1.00
SCHEMBL13318957 1.00
SCHEMBL158491 1.00
SCHEMBL30562964 1.00
SCHEMBL3696195 0.88 SLC1A2 (0.62)
SCHEMBL3696199 0.88 SLC1A2 (0.62)
SCHEMBL8530336 0.86 SLC1A2 (0.60)
SCHEMBL8126946 0.86 SLC1A2 (0.60)
SCHEMBL25662044 0.86 SLC1A2 (0.60)
SCHEMBL25660492 0.85 SLC1A2 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024238632-A2 ASYMMETRIC CIRCULAR TANDEM REPEAT PROTEINS Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (US) 2024-11-21 WO claimed
US-5688771-A Lipophilic oligopeptides with immunomodulating activity BIOCHEM PHARMA INC. (CA) 1997-11-18 US claimed
CN-122075733-A Preparation method and application of linker medicine and antibody-medicine conjugate thereof 2026-05-26 CN disclosed
CN-122031713-A Preparation method and application of linker medicine and antibody-medicine conjugate thereof 乐普生物科技股份有限公司 2026-05-15 CN disclosed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 US disclosed
EP-4659764-A1 LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF Lepu Biopharma Co., Ltd. (CN) 2025-12-10 EP disclosed
CN-120682140-A Preparation method of (2S) -3-cyano-2-methyl-4-oxo piperidine-1-carboxylic acid tert-butyl ester 内蒙古幸源新材料科技有限公司 2025-09-23 CN disclosed
CN-114585637-B MASP-inhibitory compounds and uses thereof 拜耳公司 2025-04-15 CN disclosed
WO-2024238632-A2 ASYMMETRIC CIRCULAR TANDEM REPEAT PROTEINS Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (US) 2024-11-21 WO disclosed
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 US disclosed
WO-2002038540-A9 ACTIVITY-DEPENDENT CYSTEINE PROTEASE PROFILING REAGENT UNIVERISTY OF CALIFORNIA (US) 2004-03-04 WO disclosed
US-20020150961-A1 Activity-dependent cysteine protease profiling reagent THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY MANAGEMENT 2002-10-17 US disclosed
WO-2002038540-A2 ACTIVITY-DEPENDENT CYSTEINE PROTEASE PROFILING REAGENT THE REGENTS OF THE UNIVERISTY OF CALIFORNIA (US) 2002-05-16 WO disclosed
US-6329502-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) JAPAN ENERGY CORPORATION (JP) 2001-12-11 US disclosed
US-6313094-B1 COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION JAPAN ENERGY CORPORATION (JP) 2001-11-06 US disclosed
EP-0490667-B1 HIV protease inhibitors JAPAN ENERGY CORP (JP) 1999-06-09 EP disclosed
US-5688771-A Lipophilic oligopeptides with immunomodulating activity BIOCHEM PHARMA INC. (CA) 1997-11-18 US disclosed
EP-0635026-A1 NOVEL LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY BIOCHEM PHARMA INC (CA) 1995-01-25 EP disclosed
EP-0490667-A2 HIV protease inhibitors JAPAN ENERGY CORPORATION (JP) 1992-06-17 EP disclosed